4.2 Review

CYP-eicosanoids-A new link between omega-3 fatty acids and cardiac disease?

Journal

PROSTAGLANDINS & OTHER LIPID MEDIATORS
Volume 96, Issue 1-4, Pages 99-108

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.prostaglandins.2011.09.001

Keywords

Cytochrome P450; Eicosanoids; EPA; DHA; Cardioprotection; Arrhythmia

Funding

  1. Deutsche Forschungsgemeinschaft (DFG) [Schu822/5, 1054]

Ask authors/readers for more resources

Fish oil omega-3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) protect against arrhythmia and sudden cardiac death by largely unknown mechanisms. Recent in vitro and in vivo studies demonstrate that arachidonic acid (AA) metabolizing cytochrome P450-(CYP) enzymes accept EPA and DNA as efficient alternative substrates. Dietary EPA/DHA supplementation causes a profound shift of the cardiac CYP-eicosanoid profile from AA- to EPA- and DHA-derived epoxy- and hydroxymetabolites. CYP2J2 and other CYP epoxygenases preferentially epoxidize the omega-3 double bond of EPA and DHA. The corresponding metabolites, 17,18-epoxy-EPA and 19,20-epoxy-DHA, dominate the CYP-eicosanoid profile of the rat heart after EPA/DHA supplementation. The (omega-3)-epoxyeicosanoids show highly potent antiarrhythinic properties in neonatal cardiomyocytes, suggesting that these metabolites may specifically contribute to the cardioprotective effects of omega-3 fatty acids. This hypothesis is discussed in the context of recent findings that revealed CYP-eicosanoid mediated mechanisms in cardiac ischemia-reperfusion injury and maladaptive cardiac hypertrophy. (C) 2011 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available